- Home
- BBIO vs ENLC Comparison
BBIO vs ENLC Comparison
Compare BBIO & ENLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBIO
- ENLC
- Stock Information
- Founded
- BBIO 2015
- ENLC 2013
- Country
- BBIO United States
- ENLC United States
- Employees
- BBIO N/A
- ENLC N/A
- Industry
- BBIO Biotechnology: Pharmaceutical Preparations
- ENLC Natural Gas Distribution
- Sector
- BBIO Health Care
- ENLC Utilities
- Exchange
- BBIO Nasdaq
- ENLC Nasdaq
- Market Cap
- BBIO 5.6B
- ENLC 6.4B
- IPO Year
- BBIO 2019
- ENLC N/A
- Fundamental
- Price
- BBIO $36.08
- ENLC $15.46
- Analyst Decision
- BBIO Strong Buy
- ENLC Hold
- Analyst Count
- BBIO 13
- ENLC 11
- Target Price
- BBIO $48.33
- ENLC $15.40
- AVG Volume (30 Days)
- BBIO 2.5M
- ENLC 2.5M
- Earning Date
- BBIO 02-20-2025
- ENLC 02-18-2025
- Dividend Yield
- BBIO N/A
- ENLC 3.45%
- EPS Growth
- BBIO N/A
- ENLC N/A
- EPS
- BBIO N/A
- ENLC 0.22
- Revenue
- BBIO $217,765,000.00
- ENLC $6,652,200,000.00
- Revenue This Year
- BBIO $2,309.33
- ENLC $1.51
- Revenue Next Year
- BBIO N/A
- ENLC $14.54
- P/E Ratio
- BBIO N/A
- ENLC $70.12
- Revenue Growth
- BBIO 2209.77
- ENLC N/A
- 52 Week Low
- BBIO $21.62
- ENLC $11.55
- 52 Week High
- BBIO $41.04
- ENLC $16.40
- Technical
- Relative Strength Index (RSI)
- BBIO 73.73
- ENLC 66.70
- Support Level
- BBIO $33.73
- ENLC $14.14
- Resistance Level
- BBIO $36.24
- ENLC $14.62
- Average True Range (ATR)
- BBIO 1.63
- ENLC 0.30
- MACD
- BBIO 0.65
- ENLC 0.16
- Stochastic Oscillator
- BBIO 97.63
- ENLC 89.50
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
About ENLC EnLink Midstream LLC Common Units representing Limited Partner Interests
EnLink Midstream LLC is an integrated midstream company. The company's operating segment includes Permian; North Texas; Oklahoma; Louisiana and Corporate. The company generates maximum revenue from the Louisiana segment. The Louisiana segment includes natural gas pipelines, natural gas processing plants, storage facilities, fractionation facilities, and NGL assets.